Silo Pharma (Nasdaq: Silo) announced a strategic expansion in the management of the cash of cryptocurrencies, by focusing on Bitcoin, Ethereum and Solana. The company has appointed an expert in cryptographic infrastructure Corwin yu As the first member of his new Crypto Advisory Council to direct this initiative.
The strategy includes opportunistic digital currency purchases and the generation of elements through development, supported by newly acquired AI market technology. Simultaneously, Silo Pharma continues his biopharmaceutical concentration, with his Drug PTSD SPC-15 Approach to submission of the FDA demand.
Silo Pharma (Nasdaq: Silo) ha annuciciciao un’espans strategica nella gesturee del tesoro in criptovaltete, concerandosi su Bitcoin, Ethereum e Solana. Azienda ha nominato l’esperto di infrasture crypto Corwin yu Come and primo membro del nuovo crypto advisory board by Guidare Questa Iniziativa.
The strategia prevede Acuvéde Opposite Di Valute Digitali e Générazione di rendimeti tramite jalting, support for una nuova tecnologia di intelligenza artificial per anisi del mercato. Contemporaneament, silo pharmae mantinen il suo focus biofarmaceutico, con il Farmaco by it ptsd SPC-15 Che si avvicina alla presented della damanda indic alla fda.
Silo Pharma (Nasdaq: Silo) ha anunciado una expansión estraégica in the gestión of tesoría in criptomonedas, childish in Bitcoin, Ethereum y Solana. La Compañía ha Designado al Corwin yu Como El Primer Miembro de Su Nuevo Crypto Advisory Board Para Liderar Esta Iniciativa.
The estrategia included Compras Oportunistas of digital monedas y generación de Radidimintos mediced jalakte, ragedada por una tecnología de inteligencia artificial para inteligencia de mercado recitmement adquirida. Simultáneamen, Silo Pharma Conti responsible Medicationo para el tpt SPC-15 Próximo to the presedación of the solicitud indicated the fda.
Silo Pharma (나스닥: Silo)가 비트코인, 이더리움, 솔라나에 중점을 암호화폐 자산 관리 전략적 전략적 확장을 확장을 발표했습니다. 회사는 이 이니셔티브를 이끌기 암호화폐 인프라 전문가 코윈 유 (Corwin yu)를 새로운 자문위원회의 자문위원회의 첫 임명했습니다.
이 전략에는 기회주의적 기회주의적 화폐 매입과 통한 통한 수익 창출이 포함되며, 새로 도입한 ai 기반 시장 정보 기술의 지원을 받습니다 받습니다. 동시에 Silo Pharma 는 생명공학 분야에 집중하며, 외상 후 스트레스 장애 (sspt) 치료제 SPC-15의 fda ind 신청 제출이 제출이.
Silo Pharma (Nasdaq: Silo) An announced an expansion of strategic in the cash gesture in cryptocurrencies, focusing on Bitcoin, Ethereum and Solana. The company has appointed the expert in crypto infrastructure Corwin yu As the first member of his new Crypto Advisory Board to manage this initiative.
The strategy includes opportunistic purchases of digital currencies and the generation of return via stuking, supported by a new intelligence technology artificial to analyze it. At the same time, Silo Pharma for the combination of threads orientation biopharmaceutical, with son PTSD SPC-15 drug drugs Who approaches the submission of the India demand to the FDA.
Silo Pharma (Nasdaq: Silo) Hat Eine Strategische Erweiterg IM Bereich der Kryptowährungs-Treasury-Verwaltung Angekündigt, Mit Fokus Auf Bitcoin, Ethereum und Solana. Das Unternehmen Hat Den Krypto-Infrastruktur-Experten Corwin yu Als Erstes Mitglied Seines Neuen Crypto Advisory Boards Berufen, Um Diese Initiative Zu Leiten.
Die strategy umfasst opportunistische käufe digitaler Währungen und Ertragsgenerierung durch Staking, untertützt durch neu erworbene ki-gregedützte marktananalysis-technology. Gleichzeitig Bleibt Silo Pharma Seinem Biopharmazeuttischen Fokus Treu, Wobei Das PTSD-MEDKAMENT SPC-15 Kurz Vor der Einreichung of the Ind-Ant-Antrags Steht.
Positive
- Diversification in the management of the treasure of cryptocurrency by emphasizing the main digital assets
- Appointment of the infrastructure expert of experienced crypto Corwin Yu to direct the strategy
- Acquisition of market intelligence technology fueled by AI for informed decision -making
- Progress with the drug PTSD SPC-15 close to the FDA indicates an application internship
Negative
- Potential volatility and risks associated with cryptocurrency investments
- Dependence on market conditions and capital available for the implementation of the strategy
- FDA approval awaiting the INP application creates regulatory uncertainty
Targeting the growth of multi-chained digital assets and the integration of decentralized finances (DEFI)
Sarasota, FL, August 05, 2025 (Globe Newswire) – Silo Pharma, Inc. (Nasdaq: Silo), announced today the launch of a cryptocurrency treasury strategy which should focus on the main digital assets, including Bitcoin, Ethereum and Sollana. The company intends to make opportunistic purchases of digital currencies after launch and to take advantage of the implementation to generate a return while focusing on the preservation of capital and the appreciation of the tokens. The extended implementation of this strategy should be based on available capital and market conditions. Silo has appointed Digital Asset Tech Pioneer, Corwin Yu, as the first member of its newly trained crypto advisory committee to direct this new strategy. To deepen this initiative, Silo recently acquired the technology of market intelligence powered by artificial intelligence, equipping the team of ideas in real time to potentially generate smarter and faster decisions.
“With the recent rise in successful cryptocurrency cash allowances and the increase in capital inputs to digital assets, we believe that there is a possibility of creating and unlocking a long-term value for Silo shareholders, from now,” said Silo CEO Eric Weisblum. “We believe that we are fortunate to appoint Corwin Yu as a main strategic advisor and head of an advisory council newly formed of three members supervising our cryptographic cash strategy, with 2 other members to appoint in the future.”
Corwin Yu is a senior manager of technology and trade with more than 20 years of experience in the construction and management of critical mission systems for institutional finance. Mr. Yu is currently a global manager of digital assets for Fintech Tsimagine, and previously he was the director of the founding technology of Markts, one of the first trading platforms of institutional crypto. In addition to these leadership roles, his previous experience lasted Pimco, Credit Suisse, hedge funds and digital asset companies. As a proven leader in cryptocurrency commercial infrastructure, fund management and regulatory compliance, Mr. Yu has a wide experience in the deployment of evolving cloud platforms and supervising cross-trading strategies. Its history include the foundation and the scaling of digital asset trading platforms, the management of world engineering and DevOps teams, and the supply of secure and compliant custody solutions.
“In addition to our launch of a digital asset cash strategy, we remain deeply engaged in our central biopharmaceutical company focused on innovative therapy for poorly served conditions,” continued Mr. Weisblum. “Our main assets, the SSPT SPC-15 medication, completes the final studies before submitting a request for medication survey (IND) of the FDA, and if such an Ind is approved, we will try to start a clinical trial of phase 1 of the first human.”
About Silo Pharma
Silo Pharma is a biopharmaceutical and diversified cryptocurrency cash company. His therapeutic accent aims to deal with poorly served conditions, including psychiatric disorders induced by stress, chronic pain and diseases of the central nervous system (SNC). The company’s portfolio includes innovative programs such as SPC-15 for SSPT, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is carried out in collaboration with the main universities and laboratories.
Prospective declarations
This press release contains “prospective declarations” within the meaning of the “Safe Harbor” provisions of the 1995 law on private security disputes. Such declarations imply risks, uncertainties and other known and unknown factors which could ensure that the real results of Silo Pharma, Inc. (“silo” or “the company”) differ considerably from the results expressed or involved by these declarations, including the changes in early sources of income, future economic and competitive conditions, difficulties in the development of technological platforms the company, retention and extent products and other factors. Consequently, although the company considers that the expectations reflected in such prospective declarations are reasonable, there is no guarantee that such expectations will prove to be correct. The company declines any obligation to update or publicly publish any revision of the prospective information contained in this press release, whether following new information, future events, or otherwise, after the date of this press release or reflect the occurrence of unforeseen events, except according to the law.
Contact
800-705-0120
[email protected]
Faq
What is the new Silo Pharma (Silo) cryptocurrency (Silo )’s cryptocurrency strategy?
Silo Pharma plans to make opportunistic purchases Bitcoin, Ethereum and SolanaUse the clearing for the generation of elements while focusing on the preservation of capital and the appreciation of tokens.
Who is Corwin Yu and what is his role at Silo Pharma?
Corwin Yu is a Senior technology and trade element Appointed as the first member of the new Silo Crypto Advisory Council. He is currently a global responsible for digital assets in Tsimagine and has more than 20 years of experience in institutional finance.
How will Silo Pharma’s cryptographic strategy affect its pharmaceutical activities?
The company declares that it remains deeply committed to his biopharmaceutical companyWith the cryptographic strategy parallel to its pharmaceutical development, including the advancement of the SSPT SPC-15 drug.
What is the status of the SSPTS medication of Silo Pharma SPC-15?
SPC-15 is Finish final studies Before submitting a new FDA (IND) request for a new medication, with plans to start phase 1 clinical trials if it is approved.
What technology will Silo Pharma use for its management of cryptographic cash?
The company has acquired Market information technology fueled by AI Provide real-time information for decision-making in its cryptocurrency cash management.
